Unknown

Dataset Information

0

Miller Fisher syndrome following Pfizer COVID-19 vaccine


ABSTRACT:

Introduction

Miller Fisher syndrome (MFS) is a rare variant of Guillain-Barre syndrome characterized by ataxia, areflexia, and ophthalmoplegia. We present a case of MFS following Pfizer COVID-19 vaccine.

Case presentation

A previously healthy 24-year-old female presented with binocular horizontal diplopia 18 days after receiving the first dose of Pfizer COVID-19 vaccine (Comirnaty®). Anti-ganglioside testing revealed positive anti-GQ1b antibodies. Intravenous immunoglobulins were administered, in a dose of 2 g per kg of body weight over 5 days. On a follow-up exam 3 weeks after the treatment, clinical improvement was noted with normal bulbomotor examination.

Conclusion

Patients with acute ophthalmoplegia occurring after COVID-19 vaccination should be screened for the presence of anti-GQ1b antibody. If the antibody is present, intravenous immunoglobulin should be administered as it may hasten clinical improvement.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10072-021-05776-0.

SUBMITTER: Abicic A 

PROVIDER: S-EPMC8611397 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7761853 | biostudies-literature
| S-EPMC10512542 | biostudies-literature
| S-EPMC10505097 | biostudies-literature
| S-EPMC8608562 | biostudies-literature
| S-EPMC8767873 | biostudies-literature
| S-EPMC7457056 | biostudies-literature
| S-EPMC8344528 | biostudies-literature
| S-EPMC9501619 | biostudies-literature
| S-EPMC9794399 | biostudies-literature
2022-10-14 | PXD031969 | Pride